Department of Urology, Adelaide & Meath Hospital, Dublin, Ireland.
Eur Urol. 2012 May;61(5):928-35. doi: 10.1016/j.eururo.2011.10.043. Epub 2011 Nov 7.
Botulinum toxin A is effective for treatment of idiopathic detrusor overactivity (IDO). The trigone is generally spared because of the theoretical risk of vesicoureteric reflux (VUR), although studies assessing injection sites are lacking.
Evaluate efficacy and safety of trigone-including versus trigone-sparing intradetrusor injections of abobotulinumtoxinA in patients with IDO.
DESIGN, SETTING, AND PARTICIPANTS: Twenty-two patients from one centre were randomised to trigone-including or trigone-sparing injections.
Injection of 500 U abobotulinumtoxinA diluted to 20ml into 20 trigone-including or trigone-sparing sites.
The primary outcome measure was total overactive bladder symptom score (OABSS) at 6 wk. The OABSS questionnaire was completed at 0, 6, 12, and 26 wk. Baseline and postinjection urodynamic studies and micturating cystourethrograms were performed. Baseline values and subsequent time points were compared by t test. A mixed-effect model was used for repeated measures in time.
For symptom scores at baseline compared with scores at 6 wk postinjection, the mean total OABSS improved from 22.4 to 8.7 (p<0.001) in the trigone-including group compared with 22.7 to 13.4 (p<0.03) in the trigone-sparing group. The difference in mean change from baseline was 4.4 points in favour of the trigone-including group (p=0.03). The total OABSS at 12 and 26 wk and the urgency subscale scores at 6, 12, and 26 wk showed significant improvement in favour of the trigone-including group. Mean postvoid residual volumes and clean intermittent self-catheterisation rates between the two groups were similar. No patients developed VUR. Performing injections under general anaesthetic was a limitation, as tolerability under local anaesthetic was not assessed. A further limitation is the lack of a trigone-only arm.
Trigone-including injections are superior to trigone-sparing injections for the treatment of refractory IDO and did not cause VUR in this study.
肉毒杆菌毒素 A 对治疗特发性逼尿肌过度活动症(IDO)有效。由于理论上存在膀胱输尿管反流(VUR)的风险,三角区通常会被避开,尽管缺乏评估注射部位的研究。
评估包括三角区在内和不包括三角区的肉毒毒素 A 膀胱内注射治疗 IDO 的疗效和安全性。
设计、地点和参与者:来自一个中心的 22 名患者被随机分为包括三角区在内和不包括三角区的两组。
在 20 个包括三角区在内或不包括三角区的部位注射 500U 阿博特毒素 A 稀释至 20ml。
主要观察指标为 6 周时总逼尿过度症状评分(OABSS)。OABSS 问卷在 0、6、12 和 26 周时完成。在基线和注射后进行尿动力学研究和排尿性膀胱尿道造影。采用 t 检验比较基线值和随后的时间点。采用混合效应模型进行时间重复测量。
与基线相比,注射后 6 周时,包括三角区在内组的平均总 OABSS 从 22.4 分改善至 8.7 分(p<0.001),而不包括三角区在内组从 22.7 分改善至 13.4 分(p<0.03)。包括三角区在内组的平均变化差值为 4.4 分,有利于包括三角区在内组(p=0.03)。12 周和 26 周时的总 OABSS 和 6、12 和 26 周时的尿急亚量表评分均有显著改善,有利于包括三角区在内组。两组间平均残余尿量和清洁间歇导尿率相似。没有患者发生 VUR。在全身麻醉下进行注射是一个局限性,因为局部麻醉下的耐受性未被评估。另一个局限性是缺乏仅三角区的组别。
对于治疗难治性 IDO,包括三角区在内的注射优于不包括三角区在内的注射,且在本研究中不会导致 VUR。